Position in UTHR
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$4,092,747
+$2,500,902 QoQ
Shares Held
6,902
+111.3% QoQ
Ownership
0.016%
of shares outstanding
% of Portfolio
1.62%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in UTHR Over Time
Shares Held
Position Value (USD)
Derivatives in UTHR
reported options exposure · as of Mar 31, 2026CallValue
$60,483
CallShares
102
PutValue
$30,241
PutShares
51
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Persistent Asset Partners Ltd holds $6,722,344 across 9 Drug Manufacturers - Specialty & Generic names. UTHR ranks #1 (60.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | UTHR |
UNITED THERAPEUTICS Corp
This page
|
6,902 | $4,092,747 | |
| 2 | ALKS |
Alkermes plc.
|
25,563 | $903,907 | |
| 3 | INDV |
Indivior Pharmaceuticals, Inc.
|
18,012 | $549,005 | |
| 4 | BIOA |
BioAge Labs, Inc.
|
15,167 | $265,270 | |
| 5 | AYTU |
Aytu Biopharma, Inc
|
92,897 | $253,608 | |
| 6 | AMRX |
Amneal Pharmaceuticals, Inc.
|
17,808 | $221,353 | |
| 7 | XERS |
Xeris Biopharma Holdings, Inc.
|
35,661 | $206,833 | |
| 8 | LNTH |
Lantheus Holdings, Inc.
|
2,642 | $200,395 |
All Filings in UTHR
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $60,483 | 102 | Call | Sole | 2026-05-12 | |
| 2026-03-31 | $30,241 | 51 | Put | Sole | 2026-05-12 | |
| 2026-03-31 | $4,092,747 | 6,902 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $1,591,845 | 3,267 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||